Literature DB >> 25292162

[Prediction in cerebrovascular diseases].

G F Hamann1.   

Abstract

Prediction of the outcome of cerebrovascular diseases or of the effects and complications of various forms of treatment are essential components of all stroke treatment regimens. This review focuses on the prediction of the stroke risk in primary prevention, the prediction of the risk of secondary stroke following a transient ischemic attack (TIA), the estimation of the outcome following manifest stroke and the treatment effects, the prediction of secondary cerebrovascular events and the prediction of vascular cognitive impairment following stroke. All predictive activities in cerebrovascular disease are hindered by the translation of predictive results from studies and patient populations to the individual patient. Future efforts in genetic analyses may be able to overcome this barrier and to enable individual prediction in the area of so-called personalized medicine. In all the various fields of prediction in cerebrovascular diseases, three major variables are always important: age of the patient, severity and subtype of the stroke. Increasing age, more severe stroke symptoms and the cardioembolic stroke subtype predict a poor outcome regarding both survival and permanent disability. This finding is somewhat banal and will therefore never replace the well experienced clinician judging the chances of a patient and taking into account the personal situation of this patient, e.g. for initiation of a rehabilitation program. Besides the individualized prediction, in times of restricted economic resources and increasing tendency to clarify questions of medical treatment in court, it seems unavoidable to use prediction in economic and medicolegal interaction with clinical medicine. This tendency will be accompanied by difficult ethical problems which neurologists must be aware of. Improved prediction should not be used to allocate or restrict resources or to restrict medically indicated treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25292162     DOI: 10.1007/s00115-014-4063-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  39 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

2.  Asymptomatic carotid lesions add to cardiovascular risk prediction.

Authors:  Salvatore Novo; Claudia L Visconti; Gisella R Amoroso; Egle Corrado; Giovanni Fazio; Ida Muratori; Rosalba Tantillo; Monica Lunetta; Luciana D'Angelo; Giuseppina Novo
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2010-10

3.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

4.  Blood pressure and clinical outcomes in the International Stroke Trial.

Authors:  Jo Leonardi-Bee; Philip M W Bath; Stephen J Phillips; Peter A G Sandercock
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

5.  Clinical usefulness of carotid ultrasound to improve stroke risk assessment: ten-year results from the Carotid Atherosclerosis Progression Study (CAPS).

Authors:  Kathrin Ziegelbauer; Carolin Schaefer; Helmuth Steinmetz; Matthias Sitzer; Matthias W Lorenz
Journal:  Eur J Prev Cardiol       Date:  2012-05-22       Impact factor: 7.804

Review 6.  Risk scores for transient ischemic attack.

Authors:  M E Wolf; V E Held; M G Hennerici
Journal:  Front Neurol Neurosci       Date:  2013-10-11

7.  Survival after stroke--the impact of CHADS2 score and atrial fibrillation.

Authors:  Karin M Henriksson; Bahman Farahmand; Saga Johansson; Signild Asberg; Andreas Terént; Nils Edvardsson
Journal:  Int J Cardiol       Date:  2009-01-13       Impact factor: 4.164

8.  Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.

Authors:  Graeme J Hankey; Susanna R Stevens; Jonathan P Piccini; Yuliya Lokhnygina; Kenneth W Mahaffey; Jonathan L Halperin; Manesh R Patel; Günter Breithardt; Daniel E Singer; Richard C Becker; Scott D Berkowitz; John F Paolini; Christopher C Nessel; Werner Hacke; Keith A A Fox; Robert M Califf
Journal:  Stroke       Date:  2014-04-17       Impact factor: 7.914

Review 9.  Predicting outcomes after transient ischemic attack and stroke.

Authors:  David A Rempe
Journal:  Continuum (Minneap Minn)       Date:  2014-04

10.  Common carotid intima-media thickness measurements do not improve cardiovascular risk prediction in individuals with elevated blood pressure: the USE-IMT collaboration.

Authors:  Michiel L Bots; Karlijn A Groenewegen; Todd J Anderson; Annie R Britton; Jacqueline M Dekker; Gunnar Engström; Greg W Evans; Jacqueline de Graaf; Diederick E Grobbee; Bo Hedblad; Albert Hofman; Suzanne Holewijn; Ai Ikeda; Maryam Kavousi; Kazuo Kitagawa; Akihiko Kitamura; M Arfan Ikram; Eva M Lonn; Matthias W Lorenz; Ellisiv B Mathiesen; Giel Nijpels; Shuhei Okazaki; Daniel H O'Leary; Joseph F Polak; Jacqueline F Price; Christine Robertson; Christopher M Rembold; Maria Rosvall; Tatjana Rundek; Jukka T Salonen; Matthias Sitzer; Coen D A Stehouwer; Oscar H Franco; Sanne A E Peters; Hester M den Ruijter
Journal:  Hypertension       Date:  2014-03-10       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.